Stay updated with breaking news from Onc L. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Greencore Group plc (GNC.L) reported that its fiscal 2023 profit before taxation increased to 45.2 million pounds from 39.8 million pounds, last year, driven by higher operating profit and lower exceptional items offset by higher finance costs.
Director Deals - (ONC)
25 May 2021 | 08:07am StockMarketWire.com - Convenience food maker Greencore reported a strong recovery since the start of the second half of the year amid easing restrictions after swinging to a loss in the first half. In the first seven weeks of the second half of 2021, pro forma revenue was approximately 64% above prior year levels and approximately 5% below equivalent pre-COVID levels in FY19 Pro forma revenue in food to go categories was running at approximately 123% above prior year levels and approximately 14% below the equivalent pre-COVID levels in FY19. The stronger start to the sec...
6 April 2021 | 07:44am StockMarketWire.com - Immunodiagnostics group Oncimmune said it had signed two separate agreements with Roche Pharmaceuticals and Cedars-Sinai Medical Center for use of the company's newly developed infectious disease panel. Oncimmune had in October announced the award of UK government funding for the development and validation of an infectious disease NavigAID panel. 'Utilising the data from this and other work, the company's current SeroTag research panel has been tailored to predict Covid-19 disease severity and therapeutic response to the virus and the effectiveness...
15 February 2021 | 07:54am StockMarketWire.com - Immunodiagnostics group Oncimmune posted a narrower first-half loss on the back of higher revenue and lower R&D spending. Pre-tax losses for the six months through November amounted to £2.8 million, compared to losses of £5.5 million year-on-year. Revenue rose to £1.8 million, up from £0.3 million. Oncimmune said it saw a 'marked increase in commercial activity' as large pharmaceutical and biotech companies utilised its biomarker discovery platform technology tools. Seven such contracts had been signed in the period, including with Roche Ph...